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Abstract
Arsenic trioxide (ATO) has been used successfully to treat acute promyelocytic leukaemia, and since this discovery,
it has also been researched as a possible treatment for other haematological and solid cancers. Even though many
positive results have been found in the laboratory, wider clinical use of ATO has been compromised by its toxicity
at higher concentrations. The aim of this study was to explore an improved method for delivering ATO using
liposomal nanotechnology to evaluate whether this could reduce drug toxicity and improve the efficacy of ATO in
treating human papillomavirus (HPV)-associated cancers. HeLa, C33a, and human keratinocytes were exposed to
5 μm of ATO in both free and liposomal forms for 48 h. The stability of the prepared samples was tested using
inductively coupled plasma optical emission spectrometer (ICP-OES) to measure the intracellular arsenic
concentrations after treatment. Fluorescent double-immunocytochemical staining was carried out to evaluate the
protein expression levels of HPV-E6 oncogene and caspase-3. Cell apoptosis was analysed by flow cytometry.
Results showed that liposomal ATO was more effective than free ATO in reducing protein levels of HPV-E6 and
inducing cell apoptosis in HeLa cells. Moreover, lower toxicity was observed when liposomal-delivered ATO was
used. This could be explained by lower intracellular concentrations of arsenic. The slowly accumulated intracellular
ATO through liposomal delivery might act as a reservoir which releases ATO gradually to maintain its anti-HPV
effects. To conclude, liposome-delivered ATO could protect cells from the direct toxic effects induced by higher
concentrations of intracellular ATO. Different pathways may be involved in this process, depending on local
architecture of the tissues and HPV status.
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Background
Cervical cancer is one of the most common types of
cancer in women, the majority of cases being caused
by high-risk human papillomavirus (HPV) including
HPV16 and 18. E6, as one of the most important
early oncogenes for HPV, increases the chance of
malignancy by binding to tumour suppressor p53 and
preventing cancer cells from undergoing apoptosis.
Therefore, disrupting E6 linkage to p53 and liberating
p53 in those HPV-infected cells may restore their al-
tered biological functions and allow cells to continue
the normal process of cell apoptosis.
Arsenic trioxide (ATO) is well known for its toxicity,
but it has also been used medicinally, with its first
recorded usage dating back to 200 B.C. in traditional
Chinese medicine [1]. Since the 1980s, a group of
Chinese clinicians have identified its anticancer property
in treating patients with acute promyelocytic leukaemia
(APL) [2–4]. Since then, ATO has been studied exten-
sively and researchers have further extended its applica-
tion to test its anticancer properties in solid cancers.
Recent studies have shown that ATO demonstrates
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anticancer activity against a variety of solid tumour
models and cancer cell lines, including lung, liver,
ovarian, cervical, breast and prostate cancers [5–10].
The mechanisms of action of ATO in treating these
cancers are still not fully understood, although cell
differentiation, apoptosis induction, angiogenesis in-
hibition and reactive oxygen species generation have
been implicated as being involved [11]. Furthermore,
much higher dosages of ATO are required for treat-
ing malignancies rising from solid cancers [12] in
comparison to haematopoietic ones due to their dis-
tinct differences in tissue architecture. Therefore,
some severe side effects from ATO may occur dur-
ing the treatment including peripheral neuropathies,
liver failure and cardiac toxicity, which could limit
its clinical utility [8, 13].
Our earlier work has shown that ATO can be used as
an agent to specifically target HPV-infected cervical
cancer cells [14]. However, it can only be used at a low
concentration (up to 2 μM) as most of cells were killed
after their exposure to high concentrations of ATO.
Therefore, an effective delivery system is needed to
improve the therapeutic index of the drug and to expand
its clinical utility to treat solid tumours.
The liposomal delivery system has been used for the
delivery of both lipophilic and hydrophilic drugs [15]. It
started from the use of conventional liposomes and has
since evolved to the development of stealth liposomes
and now targeting liposomes. Most recently, it has been
successfully used in different applications including
treating gliomas [16, 17] and breast cancers [18, 19]
and managing infectious and inflammatory disorders
[20] and heart diseases [21, 22]. In addition, other
nanocarrier-delivering systems including using polymer-
drug conjugates, dendrimers, micro/nano-particles and
micelles also emerged and have been used in various
applications along with liposomal-delivering systems
[22, 23]. Current nanotechnology provides us a superb
and promising opportunity to guide the targeting
ligands directly to the target sites with minimal dis-
turbance to the surrounding cells and tissues, which
holds our hope for defeating cancers including HPV-
associated cancers one day.
Chen and co-workers have shown that targeted li-
posomal delivery of ATO potentiates its efficacy in
relatively insensitive solid tumours [24, 25]. To our
knowledge, no work has been done to investigate the
effects of ATO delivered by liposomes on the tre-
atment of HPV-associated cancers. Therefore, an in
vitro study was carried out to investigate the antican-
cer effects of liposomal-encapsulated ATO in
comparison to free form ATO through the evaluation




Soy phosphatidylcholine (PC) was purchased from Avanti
Polar Lipids (AL, USA). Methoxypolyethyleneglycol-di-
stearoyl-phosphatidylethanolamine (DSPE-PEG2000; with
mPEG MW2000Da) was obtained from Genzyme (UK).
Cholesterol (Chol), PBS, Triton-100, ATO, nickel acetate
and dialysis tubing were purchased from Sigma (UK).
Methanol and dichloromethane were from Thermofisher
(UK). RPMI1640, L-glutamine, penicillin-streptomycin
and foetal bovine serum (FBS) were from Invitrogen Life
Technologies (UK).
Liposome Preparation and Characterization
Liposomes were composed of soy PC, cholesterol, and
methoxypolyethyleneglycol-di-stearoyl-phosphatidyletha-
nolamine (DSPE-PEG2000; Genzyme). Liposomes were
prepared as described elsewhere [24]. Briefly, the lipids
were dissolved in methanol: dichloromethane1:2 (v/v) at a
PC/cholesterol/DSPE-PEG2000 molar ratio of 54.7:45:0.3
at room temperature. The lipid mixtures were deposited
on the side wall of the rotary glass vial by removing the
solvent with nitrogen. The dried lipid films were hydrated
in 730 mM nickel acetate (Ni(OAc)2) aqueous solutions.
This process led to the spontaneous formation of pegy-
lated liposomes. The liposome suspension was subse-
quently subjected to 10 freeze-and-thaw cycles (freezing
in liquid nitrogen for 3 min and thawing in 37 °C water
bath for 3 min). The liposomes were then downsized by
passing through 0.1-μm Anotop 10 filters (Whatman,
UK). Extruded liposomes were dialysed against 10 mM
sodium phosphate buffer at pH 7 to get rid of excess
Ni(OAc)2. The Ni(OAc)2-encapsulated liposomes were
then incubated with an ATO solution at room temperature
for 2.5 h. After removal of extra unencapsulated ATO by
dialysis, the concentrations of phospholipids (P), encapsu-
lated ATO and nickel (Ni) in the liposomes were deter-
mined by inductively coupled plasma optical emission
spectrometer (ICP-OES; Thermo-Scientific iCap 6500
ICP, UK). The molar ratios of ATO/lipid were calcu-
lated and used to assess loading efficiency and liposome
stability. The mean liposome sizes were determined
by dynamic light scattering on a Zetasizer-Nano ZS
(Malvern Instruments, UK).
Cell Culture
Two cervical cancer cell lines, HeLa and C33a (ATCC,
USA), and a control cell line, human keratinocytes (HK)
(Life Technologies, UK), were used in this study. HeLa
cells (HPV18 positive = 10 copies per cell) and C33a
(HPV negative) were cultured in RPMI1640 media con-
taining 10 % foetal calf serum, 100 U/ml of penicillin
and 100 mg/ml streptomycin in 75-cm2 flasks. The cells
were grown in a humidified incubator containing 5 %
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CO2 and 95 % air at 37 °C until they reached 90 %
confluence. The following experiments were then set up
for further studies following 48-h ATO exposure: quanti-
fication of cellular arsenic uptake, fluorescent double im-
munocytochemistry staining (HPV18 E6 and Caspase-3)
and flow cytometry analysis for cell apoptosis.
Quantitative Analysis of Cellular Uptake of Arsenic by
ICP-OES
Cells were seeded into four 25-cm2 flasks at 2 × 105
cells/flask. Following a 24-h cell attachment, cells were
treated as described below: control (cells in RPMI
media), ATO 5 μM (ATO5), liposomes only (Lip) and
lipo-ATO 5 μM (ATO5 + Lip). After 48 h, the cells were
washed by PBS then trypsinized before they were
collected into Falcon tubes for further analysis. Cells
were extracted by adding 3–7 ml of nitric acid and
transferred to Teflon tubes to be digested in a MarsX-
press microwave (Method EPA 3051A, 2007). The cell
extracts were then transferred to centrifuge tubes, and
arsenic concentration was analysed using ICP-OES. The
concentration of arsenic was corrected by cell number
and total volume accordingly.
HPV-E6 and Caspase-3 Expression Levels Analysed by
Confocal Microscopy
The cells were counted and seeded at a density of
5 × 104/ml on sterile cover slips placed in six-well plates.
The cells were grown for overnight attachment before
exposing to the drug treatment. After 48 h of drug treat-
ment, the cells grown on cover slips were washed and
fixed with 4 % paraformaldehyde in PBS for 10 min before
immunocytochemical staining.
Fixed cells on coverslips were immunostained using a
double fluorescent staining method by labelling HPV-E6
protein with fluomore cyanine 5 (in red) and active
caspase-3 protein (Abcam, Cambridge, UK) using fluor-
escein isothiocyanate (FITC; in green) as described
previously [14]. Briefly, cells were permeablized by 0.2 %
Triton-100, followed by 50 % horse serum for blocking.
The first primary antibody, monoclonal anti-HPV16 E6/
HPV18 E6 (Santa Cruz Biotechnology, Heidelberg,
Germany) at a 1 in 150 dilution in PBS, was applied for
90 min at room temperature, followed by 30 and 20 min
of secondary and tertiary antibodies, using an ABC
universal kit (Vector Lab, Peterborough, UK). The
tyramide signal amplification reagent conjugated by
cyanine 5 (TSA-Cy5, PerkinElmer, Waltham, MA, USA)
was then applied to detect any horseradish peroxidase-
conjugated antibody bound to HPV-E6 protein.
Next, goat serum was applied before polyclonal rabbit
antihuman caspase-3 antibody (Abcam, UK) at a 1 in
100 dilution and was incubated with cells for 60 min.
FITC-labelled HRP-conjugated anti-rabbit IgG (Sigma,
Dorset, UK) was added afterwards, followed by mount-
ing using 6-diamidino-2-phenylindole (DAPI; staining
nuclei in blue) containing anti-fade ProLong Gold reagent
(Life Technologies Ltd, Paisley, UK). The fluorescence
emitted from each slide was observed via a confocal
microscope (Leica Microsystems, Wetzlar, Germany) and
images were recorded accordingly.
Analysis of Cell Apoptosis by Flow Cytometry
Cells were seeded at 5 × 105/ml in six-well culture plates
and grown overnight before exposing to the drug. After
48 h of drug treatment, the cells were trypsinized, washed
twice by PBS and then collected into 15-ml centrifuge
tubes for further staining. The cells were re-suspended in
Annexin-V binding buffer (BD, Oxford, UK) before incu-
bating with monoclonal antibody Annexin-V conjugated
with Alexa 488 (10 μg/ml) (Sigma, UK) for 30 min avoid-
ing light. Propidium iodide (PI; 1 μg/ml) (Sigma, UK)
was added afterwards, and all samples were analysed
within 1 hr of PI staining using FACSCalibur (BD,
Oxford, UK).
Statistical Analysis
Statistical analysis was carried out automatically follow-
ing flow cytometry analysis through BD Calibur software
provided. Mean and coefficient of variation (CV) were
calculated accordingly.
For immunostaining results from confocal microscopy,
an average number from positively stained cells in a total
of six fields of each sample were calculated and average
percentages were recorded.
Results
Liposome Preparation and Characterization
The phospholipids (P), encapsulated As, and Ni in the
liposomes were quantified by ICP-OES. The concentra-
tions of P, As and Ni in the liposomes are presented in
Table 1. The mean sizes of control liposomes and
liposomes with ATO determined by dynamic light scat-
tering on a Zetasizer-Nano ZS (Malvern Instruments)
were 118.9 ± 0.7 and 121.0 ± 2.4 nm, respectively, with
polydispersity of 0.1. The liposome suspension was
stored at 4 °C for 1 month, and the leakage of As from
liposomes was examined every week (Fig. 1). More than
85 % of ATO remained encapsulated in the liposomes
Table 1 Characterization of the liposomes by ICP-OES
Sample P (mM) As (mM) Ni (mM) As/P
Lipo-ATO 2.37 ± 0.03 0.78 ± 0.23 2.71 ± 1.63 0.33
Control lipo 2.22 ± 0.04 ND 2.81 ± 0.12
Data are shown as means ± standard deviations of three
replicate measurements
ND lower than detection limit
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after 1 month. No significant change in size or charge
was observed (Fig. 2).
Quantitative Analysis of Arsenic Uptake
Cells were incubated with the four samples: control
(cells in RPMI media), ATO 5 μM (ATO5), liposomes
only (Lip) and lipo-ATO 5 μM (ATO5 + Lip) for 48 h.
The cellular concentration of arsenic was determined by
ICP-OES (Table 2). Results showed that arsenic uptake
was significantly decreased in all three cell lines when
ATO was delivered by liposomes (ATO5 + LIP) in
comparison to free ATO (p < 0.001). In addition, the
highest arsenic uptake was observed in HeLa cells, and
no arsenic was detected in any of the cell lines when
treated with cell media or control liposomes (Table 2).
Analysis of Cell Apoptosis by Flow Cytometry
HK, C33a and HeLa cells were labelled by FITC-
conjugated Annexin-V and PI for the detection of early
apoptotic and late apoptotic cells, respectively. The
fluorescence was detected on FL1 and FL3 channels,
respectively, by flow cytometer. The percentage of cell
population distributed in different quadrants represents
early apoptotic cells (lower right quadrant, Annexin+ PI−),
late apoptotic/necrotic cells (upper quadrant, PI+) and live
cells (lower left quadrant, Annexin− PI−) (Fig. 3). The
percentage of the distribution for each cell population is
summarized in Table 3. More than 90 % of the cells were
alive when treated with cell media or control liposomes.
For HeLa and C33a cells, more apoptotic cells were
observed when treated with free ATO in comparison to
liposomal-delivered ATO, whilst less than 1 % of normal
HK cells underwent apoptosis after exposure to ATO.
Analysis of Protein Expression of E6 and Caspase-3
HeLa, C33a and HK cells were double immunostained
for HPV16/18 E6 and caspase-3 after a 48-h exposure to
5 μM free ATO or liposomal ATO. All cell lines were
examined under confocal microscopy. No HPV16/18 E6
expression was observed in C33a or HK cells as
Fig. 1 Percentage of ATO encapsulated in the liposome over a
1-month period of storage at 4 °C. Data are shown as
means ± standard deviations
Fig. 2 Diameter and zeta potential of the liposome formulations over a 1-month period. Data are means ± standard deviations of three replicate
measurements in one representative experiment of at least two independent experiments. Using unpaired t test (p > 0.05), no significant change
in diameter or zeta potential of liposomes was observed after the 1-month storage at 4 °C
Table 2 Arsenic concentrations in three cell lines determined
by ICP-OES after a 48-h treatment. Four samples are control
(cell media), LIP (control liposome), ATO5 and ATO5 + LIP
Samples μg/L (mean ± SEM)
HeLa C33a HK
Control ND ND ND
LIP ND ND ND
ATO5 18.4 ± 0.23 3.81 ± 0.08 1.95 ± 0.11
ATO5 + LIP 4.25 ± 0.13 1.54 ± 0.16 ND
Data presented are means ± standard deviations of three replicate treatments
in one representative experiment
ND lower than detection limit
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expected (Fig. 4). After treatment with ATO, HPV16/18
E6 expression level was decreased and caspase-3 protein
level was elevated. This effect was further enhanced
when ATO was delivered by liposomes, where E6 was
completely absent from HeLa cells and caspase-3 stain-
ing was much stronger (Fig. 4). Caspase-3 level was
slightly increased in C33a and HK cells when treated
with ATO.
Discussion
The link between HPV and cervical cancer is well defined
[26–29], but treatment options are limited. Currently,
there is renewed interest in exploring the possibilities of
treatment with ATO [14, 30, 31], which is an effective
apoptosis-inducing agent in malignant tumour cells.
However, the systematic toxicity of ATO has prevented its
widespread use in medical applications, particularly at
concentrations higher than 5 μM. We have shown previ-
ously that ATO at low dosage (≤2 μM) could specifically
target HPV-infected cervical cancer cells by inducing cell
apoptosis and increasing the expression of p53 [14]. How-
ever, most of the cells were killed when the concentration
of ATO was increased to 5 μM due to the drug toxicity,
regardless of the status of HPV infection. In this study, we
investigated the possibility of improving the therapeutic
index of ATO and eliminating its off-target toxicity by
delivering the drug within a liposomal formulation.
ATO was trapped within liposomes with the aid of co-
encapsulated transition metal ions (Ni2+) which formed
‘nanobins’ with arsenic and remained stable inside the
liposome [25]. Our stability test results showed that less
than 15 % of arsenic was lost from the liposomes over a
Fig. 3 Flow cytometry analysis of populations of live cells, early apoptotic cells and late/necrotic cells from three cell lines (HK, C33a and HeLa
cells) after a 48-h treatment with a control (cell media), b LIP (control liposome), c ATO 5 μm, and d ATO 5 μm+ LIP. FL1—detecting early
apoptotic cells by Annexin-V conjugated with FITC; FL3—detecting late apoptotic cells by DNA dye PI
Table 3 Flow cytometry analysis showing different stages of






Control HK 0.2 0.1 99.7
C33a 1.3 5.6 93.4
HeLa 1.8 4.9 93.3
LIP HK 0.1 0.1 99.8
C33a 0.6 5.9 93.5
HeLa 3.0 5.9 91.1
ATO5 HK 0.2 0.4 99.4
C33a 93 2 5
HeLa 2 60 38
ATO5 + Lip HK 0.1 0.1 99.8
C33a 4 10 86
HeLa 3.4 8.4 88.2
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4-week storage at 4 °C (Fig. 1) and the size of the
liposomes remained the same.
In this study, HPV-infected cervical cancer HeLa cells
were employed to investigate the effects of ATO when
delivered in free or encapsulated in liposomes. HPV-
negative cervical cancer cells, C33a, were used as a
control cell line along with normal HK cells. After a 48-
h treatment of ATO, ICP-OES results showed that more
arsenic was transported intracellularly when the free
drug was applied, with concentrations of 18.4 ± 0.23,
3.81 ± 0.08 and 1.95 ± 0.11 μg/l found in HeLa, C33a and
HK cells, respectively. For liposomal-delivered ATO,
intracellular arsenic levels were found to be between
three and five times lower compared to the free drug-
treated cervical cancer cells, and arsenic concentration
was undetectable in HK cells. This confirmed that
liposome encapsulation reduced the cellular membrane
permeability to ATO as indicated by Chen et al. [25],
allowing a slow build-up of ATO which was sufficient to
reduce HPV oncogene E6 levels and also result in reduced
cellular toxicity.
Investigation of rates of apoptosis as measured by flow
cytometry showed little or no toxicity of ATO towards
HK cells, with more than 99 % of HK cells remaining
alive following both treatment regimes with ATO. This
finding was consistent with the confocal microscopy
results. Furthermore, control liposomes encapsulating Ni
only were not toxic to any cells within the concentration
range of ATO used in this study. A higher percentage of
live HeLa and C33a cells were found to remain following
treatment with liposomal ATO compared to treatment
with free ATO (Table 3). This could be a result of the
significantly lower concentrations of intracellular arsenic
detected by ICP-OES (Table 2) in comparison to free
ATO-treated samples.
Confocal microscopy results showed that the two
cervical cell lines used in this study have reacted differ-
ently following exposure to ATO. HPV oncogene E6
expression was down-regulated in HeLa cells after
treatment with free ATO and was also depleted after
treatment with liposomal ATO. Meanwhile, caspase-3
level was much more up-regulated in HeLa cells
Fig. 4 Confocal fluorescent microscopic examinations (×400) of HPV-E6 (red) and caspase-3 (green) in HeLa, C33a and HK cells after a 48-h treatment.
Cells were counter-stained with DAPI (blue) to reveal the nuclear/DNA location. a Control. b LIP. c ATO 5 μM. d ATO 5 μM+ LIP. Scale bar= 20 μm
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incubated with liposomal ATO compared to that with
free ATO. These findings were supported by the results
from flow cytometry which showed a decreased percent-
age of late apoptotic cells and an increased percentage of
live cells after a 48-h exposure to liposomal ATO com-
pared with exposure to free ATO. This suggests that
ATO can specifically target HPV-infected cells and,
when delivered by liposomes, it may be able to alter
the features of the cells, converting them from cancer
cells to normal cells without causing any toxicity, al-
though more research needs to be carried out to elu-
cidate the mechanism involved.
C33a cells appear to be more sensitive to the high
concentration of free ATO with the majority of cells found
to be in the stage of early apoptosis (Table 3). However,
drug toxicity was greatly reduced when ATO was in an
encapsulated form, with most of the cells revived from
early apoptotic stage. It was also observed that C33a cells
formed small clusters following treatment with liposomal
ATO, which differed from the pattern seen with HeLa
cells. This suggests that different mechanisms of ATO
action may be involved in this process, which could be
HPV relevant. As shown by flow cytometry, no cytotox-
icity was observed from control liposomes which was also
confirmed by confocal microscopy. Normal HK cells were
found not to react with either the free or liposome-
delivered drug, which was supported by both fluorescent
confocal microscopy and flow cytometer analysis.
Recent published work by Cao and the others [19]
demonstrated that using targeted ligand can enhance the
uptake of delivered agents by the targeted cells, which
will accumulate in the cells and therefore will lead
higher cellular toxicity locally. Our study can be further
extended to investigate the effects of ATO on different
solid tumours by using targeting liposomes which can
deliver the drug to a specific cellular compartment to
enhance its efficacy and reduce its systemic toxicity.
Furthermore, co-administered drugs may improve the
pharmacokinetics profiling for the liposomal-delivered
drug in breast cancer treatment [18], which can be
further explored in our prospective study.
Conclusions
We have shown a promising strategy for targeting HPV-
infected cells using liposomal-encapsulated ATO. This
carrier system can potentially provide a therapeutic ap-
proach that may act to revert the HPV-infected cancer cells
back to a healthier cell population with reduced levels of
HPV-E6 oncogene. ATO can be stably encapsulated into
liposomes with transition metal ions (Ni2+), and the result-
ing liposomes revealed higher anti-HPV efficacy against
HeLa cells, which are less sensitive to free ATO. Further
studies are needed to elucidate the mechanisms involved.
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